title: Rimonabant for treating tobacco dependence.
abstract: Tobacco use continues to cause 5 million preventable deaths worldwide each year. Despite effective treatments being available, these are underutilized and cessation rates remain low. As tobacco use has complex physiological effects, there are multiple opportunities for novel pharmacological agents to play a role in a comprehensive treatment plan. The endocannabinoid system has been linked to the nicotine reward pathways in animal models. Rimonabant, a selective cannabinoid receptor (type 1) blocker, has been shown in some early clinical trials to have some positive effects in increasing abstinence rates of smokers attempting to stop. In addition, smokers who stop smoking with the assistance of rimonabant may gain less weight than those using placebo. However, the results from these few trials have not been entirely consistent and so its role as an aid to smoking cessation remains to be determined.
authors: University of Medicine and Dentistry of New Jersey-School of Public Health, Tobacco Dependence Program, New Brunswick, NJ 08901, USA. michael.steinberg@umdnj.edu
authors: Michael B
authors: MB
authors: Steinberg
authors: Jonathan
authors: J
authors: Foulds
mesh_terms: D000818:Animals; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors; D006801:Humans; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant; D012907:Smoking / Q000188:drug therapy* / Q000453:epidemiology; D016540:Smoking Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000188:drug therapy*
chemical_list: D063385:Cannabinoid Receptor Modulators; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant
references: Arch Intern Med. 2000 Nov 13;160(20):3128-34
references: 11074742
references: JAMA. 2006 Jul 5;296(1):64-71
references: 16820548
references: Cochrane Database Syst Rev. 2004;(3):CD000146
references: 15266423
references: Cochrane Database Syst Rev. 2004;(4):CD000031
references: 15494986
references: JAMA. 1999 Jan 6;281(1):72-6
references: 9892454
references: BMJ. 1999 Jan 30;318(7179):285-8
references: 9924052
references: N Engl J Med. 1999 Mar 4;340(9):685-91
references: 10053177
references: Neuropsychopharmacology. 2005 Jan;30(1):145-55
references: 15292905
references: Lancet. 2005 Apr 16-22;365(9468):1389-97
references: 15836887
references: Addict Biol. 2005 Sep;10(3):219-31
references: 16109583
references: CA Cancer J Clin. 2005 Sep-Oct;55(5):281-99; quiz 322-3, 325
references: 16166074
references: N Engl J Med. 2005 Nov 17;353(20):2121-34
references: 16291982
references: Expert Opin Investig Drugs. 2006 Feb;15(2):107-16
references: 16433591
references: Prev Med. 2006 Feb;42(2):114-9
references: 16375954
references: Psychopharmacology (Berl). 2006 Mar;184(3-4):504-13
references: 16416159
references: J Am Coll Cardiol. 2006 May 16;47(10):1919-26
references: 16697306
references: JAMA. 2006 Jul 5;296(1):47-55
references: 16820546
references: JAMA. 2006 Jul 5;296(1):56-63
references: 16820547
references: Nat Med. 2002 May;8(5):447-9
references: 11984581